相关实验视频

Updated: May 22, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

在复发性多发性硬化症中,托莱布鲁丁尼与特里弗卢诺米德对比

Jiwon Oh¹, Douglas L Arnold^2,3, Bruce A C Cree⁴

¹St. Michael's Hospital, University of Toronto, Toronto.

The New England journal of medicine

|April 9, 2025

概括

在降低复发性多发性硬化症患者的复发率方面,托莱布鲁丁尼比特里弗卢诺米德没有表现出优势. 使用托莱布鲁丁尼,残疾恶化减少,但出血事件更频繁.

科学领域:

神经学神经学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

托莱布鲁替尼是口服布鲁顿的氨酸激酶抑制剂,旨在向多发性硬化症中神经炎症.
需要进一步的研究来确定其在复发性多发性硬化症 (RMS) 中的疗效和安全性.

研究的目的:

在复发性多发性硬化症患者中,与特里弗卢诺米德相比,评估托莱布鲁替尼的疗效和安全性.
评估托莱布鲁丁尼布对年度复发率和残疾进展的影响.

主要方法:

进行了两个第三期,双盲,双模拟,事件驱动的试验 (GEMINI 1和GEMINI 2).
患有RMS的参与者被随机分配给接受托莱布鲁替尼 (每天60毫克) 或特里弗卢诺米德 (每天14毫克) 和匹配的安慰剂.
主要终点是年复发率;一个关键的次要终点是确认残疾恶化.

主要成果:

在这两项试验中,托莱布鲁丁尼布在降低年复发率方面并不优于特里弗卢诺米德.
综合分析显示,在托莱布鲁丁尼布组中,证实残疾恶化的参与者比例较低 (8.3%对11.3%).
副作用的发生率相似,但较小的出血事件 (疹,严重的月经) 与托莱布鲁替尼比较常见.

结论:

在降低复发性多发性硬化症患者每年复发率方面,托莱布鲁丁尼比特里弗卢诺米德没有表现出优势.
虽然托莱布鲁丁尼布在延迟残疾恶化方面显示出潜在的益处,但增加出血风险需要考虑.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...